Cargando…

122. Dalbavancin Use in Patients with Substance Use Disorders

BACKGROUND: Dalbavancin, a lipoglycopeptide antibiotic, has an extended half-life that allows for weekly dosing and is an alternative to daily intravenous (IV) antibiotics. The dosing interval has the potential to expand treatment options for more severe infections in patients with substance use dis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Streifel, Amber C, Makadia, Jina, Luke, Strnad, Douglass, Alyse, Mayer, Heather, Young, Kathleen, Lewis, James, Sukerman, Ellie, Sikka, Monica
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Poster Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777264/ http://dx.doi.org/10.1093/ofid/ofaa439.432

Ejemplares similares

1268. Dalbavancin for the Treatment of Infections due to Staphylococcus aureus
por: Streifel, Amber C, et al.
Publicado: (2020)

The hidden cost of dalbavancin: OPAT RN time required in coordination for persons who use drugs
por: Douglass, Alyse H., et al.
Publicado: (2023)

625. The Hidden Cost of Dalbavancin: OPAT-RN Time Spent on Coordination for Patients with Substance Use Disorder
por: Douglass, Alyse, et al.
Publicado: (2021)

1762. A Review of Antibiotic Outcomes Data Utilizing the Multidisciplinary OPTIONS-DC Conference for PWUD
por: Douglass, Alyse H, et al.
Publicado: (2022)

1028. Dalbavancin Use in Complicated Infections and-associated Cost-Savings
por: Streifel, Amber C, et al.
Publicado: (2019)

1004. Dalbavancin Use and Associated Cost-Savings: An Update
por: Streifel, Amber C, et al.
Publicado: (2022)

597. Comparison of Vancomycin and Daptomycin Complications and Interventions in Outpatient Parenteral Antimicrobial Therapy
por: Nakrani, Monark, et al.
Publicado: (2020)

742. The Development, Implementation, and Feasibility of Multidisciplinary Treatment Planning Conference for Individuals with Unstable Substance Use Disorders and Active Infections Requiring Prolonged Antimicrobial Therapy: The OPTIONS-DC Model
por: Strnad, Luke, et al.
Publicado: (2019)

188. Outcomes After Implementing the OPTIONS-DC Multidisciplinary Care Conference for Patients with Substance Use Disorders and Severe Bacterial Infections
por: Schneider, Brenton J, et al.
Publicado: (2021)

Screening for co-infections in patients with substance use disorders and severe bacterial infections
por: Varley, Cara D., et al.
Publicado: (2022)

Description and outcomes of patients with substance use disorder with serious bacterial infections who had a multidisciplinary care conference
por: Conte, Michael, et al.
Publicado: (2022)

788. Outcomes of Multidisciplinary Care Conferences for Patients with Substance Use Disorders Requiring Prolonged Antimicrobial Therapy for Severe Infections
por: Gore, Sara J, et al.
Publicado: (2019)

614. Evaluating the Use of Dalbavancin for Off-Label Indications
por: Taylor, Katherine, et al.
Publicado: (2021)

“OPTIONS-DC”, a feasible discharge planning conference to expand infection treatment options for people with substance use disorder
por: Sikka, Monica K., et al.
Publicado: (2021)

687. Use of Dalbavancin in Gram-positive Infective Endocarditis: Review of Current Literature
por: Fazili, Tasaduq, et al.
Publicado: (2021)

177. Implementation of Pharmacist-Driven Penicillin Allergy Evaluation and Testing with a Focus on Bypassing Penicillin Skin Testing at an Academic Medical Center
por: Ham, YoungYoon, et al.
Publicado: (2020)

589. Use of Dalbavancin in Facilitating Discharge of High Risk Patients in Low Resource Settings
por: Milgrom, Alexander
Publicado: (2020)

The challenge of antibiotic selection in prosthetic joint infections due to Corynebacterium striatum: a case report
por: Streifel, Amber C., et al.
Publicado: (2022)

Dalbavancin
por: Barberán, José, et al.
Publicado: (2021)

The pharmacokinetics of dalbavancin in subjects with mild, moderate, or severe hepatic impairment
por: Dowell, J, et al.
Publicado: (2008)

Dalbavancin safety in the phase 2/3 clinical development program
por: Seltzer, E, et al.
Publicado: (2008)

Dalbavancin dosage adjustments not required for patients with mild to moderate renal impairment
por: Dowell, J, et al.
Publicado: (2008)

314. A Retrospective Review of Dalbavancin Utilization at an Academic Medical Center
por: Napoli, Emma, et al.
Publicado: (2020)

1553. Efficacy and Safety of Dalbavancin and Oritavancin in the Treatment of Gram-Positive Infections
por: Brown, Vanessa, et al.
Publicado: (2020)

1801. About Damn Time: HAV, HBV, and Tetanus Screening and Vaccination during Hospitalization in Persons who Use Drugs
por: Streifel, Amber C, et al.
Publicado: (2023)

Evaluating the Use of Dalbavancin for Off-Label Indications
por: Taylor, Katherine, et al.
Publicado: (2022)

2902. Dalbavancin Use in Bone and Joint Infections
por: Sanikommu, Srivani, et al.
Publicado: (2023)

1056. Safety and Tolerability of Dalbavancin in Vancomycin Allergic Patients – A Case Series
por: Freeman, Kennedy J, et al.
Publicado: (2021)

162. Assessment of Beta-lactam Allergies as Rationale for Receipt of Vancomycin for Surgical Prophylaxis
por: Tucker, Kendall J, et al.
Publicado: (2020)

279. Dalbavancin for Bloodstream Infections and Endocarditis: Real-World Outcomes From the DRIVE Registry
por: Gonzalez, Pedro, et al.
Publicado: (2020)

613. Clinical Outcomes Following Dalbavancin Administration during Outpatient Parenteral Antimicrobial Therapy
por: Tuan, Jessica, et al.
Publicado: (2021)

Use of dalbavancin in infective endocarditis: a case series
por: Guleri, Achyut, et al.
Publicado: (2021)

1247. Dalbavancin in Osteomyelitis and Joint Infections: An Analysis From an Observational, Multicenter, Retrospective Cohort Study of the Real-World Use in Adult Patients
por: Diaz, Julia Garcia, et al.
Publicado: (2020)

599. Dalbavancin Utilization in Rural Healthcare Setting: A Single Center Three Years’ Experience
por: AlSalman, Ahmad, et al.
Publicado: (2020)

217. Antimicrobial Activity of Dalbavancin against Gram-Positive Bacteria Isolated from Patients Hospitalized with Bacteremia in United States and European Medical Centers: Results from the International Dalbavancin Evaluation of Activity (IDEA) Program (2018-202)
por: Sader, Helio S, et al.
Publicado: (2021)

238. Antimicrobial Activity of Dalbavancin against Gram-Positive Bacteria Isolated from Patients with Bone and Joint Infections from the United States (US) and Europe (2016-2020): Results from the International Dalbavancin Evaluation of Activity (IDEA) Program
por: Sader, Helio S, et al.
Publicado: (2021)

P122 Comparison of sleep estimation using Apple Watch accelerometry against polysomnography
por: Roomkham, S, et al.
Publicado: (2021)

Dalbavancin: a novel antimicrobial
por: Chen, A Y, et al.
Publicado: (2007)

Dalbavancin Use for the Treatment of Methicillin-resistant Staphylococcus aureus Pneumonia
por: Barber, Katie E., et al.
Publicado: (2017)

1321. Population Pharmacokinetic (PK) and Pharmacokinetic/Pharmacodynamic (PK/PD) Target Attainment Analyses for Dalbavancin in Pediatric Patients
por: Carrothers, Timothy J, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_4j382psar6bfcm4v4tihjphmdv